Neoplasm Flashcards
Squamous cell carcinoma associated with
Cavitation
Pancoast syndrome
Hypercalcemia
Squamous cell carcinoma immunohistochemistry
P63
Cytokeratin 5/6
TTF negative
Adenocarcinoma immunohistochemical stains
Thyroid transcription factor-1
Napsin A
Typical carcinoid treatment
Limited resection and lymph node dissection
Atypical carcinoid treatment
Lobe to my ad mediastinal lymph node dissection
Metastatic carcinoid treatment
No known benefit of chemotherapy or radiation
Small cell immunohistochemistry
Thyroid transcription factor-1
CD 56
Synaptophysin
Chromogranin
Inter group 0139 trial
IIIA/N2 disease no benefit from surgery after chemo/RT, can try lobectomy
Metastatic angiosarcoma pulmonary findings
Cystic > cavitation lesions, can extend to the subpleural space leading to spontaneous pneumothorax
Metastatic SCC pulmonary findings
Solid and cavitary lesions, NO cysts
t(11;19) (q21;p13)
Mucoepidermoid carcinoma
Cytarabine complications
Bone marrow suppression
Cerebellar ataxia in high doses
Daunorubicin and other anthracycline complications
Cardio toxicity
Promotion of secondary hematologic malignancies
Etoposide complications
Bone marrow suppression
Nausea and Vomiting
Can promote secondary malignancies
Bronchial granular cell tumors characteristics
Rare and mostly benign
commonly originate from tongue and skin
Tend to develop in 3rd and 4th decade
Bronchial granular cell tumor staining
S-100 protein
Vimentin
PAS
Solitary fibrous tumor of the pleura markers
CD34
BCL2
CD99
Vimentin
Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH) epidemiology
Women (92%)
Mean age 58-65
Nonsmokers
Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH) diagnosis
Cough, dyspnea, wheezing Decreased DLCO and airflow limitation CT showing mosaic attenuation, profuse subcentimeter nodules Requires surgical lung biopsy Bronchoscope 20% yield
Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH) pathology
Due to enhanced neuroendocrine cell hyperplasia and associated peptide secretion, peribronchial fibrosis and small airway obliteration occur c/w obliterating bronchiolitis
Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH) markers
Increased expression of markers of cell-cycle proliferation: Ki-67, p53, p16 = premalignant condition
Hypervascular massess in middle mediastinum
Angiofollicular lymph node hyperplasia (Castleman’s disease)
Vascular malformations
Metastatic disease
Paragangliomas
Hypervascular massess in anterior mediastinum
Ectopic parathyroid adenomas
Thymic carcinoids
Hypervascular massess in posterior mediastinum
Neurogenic tumors
Differentiation Syndrome symptoms
AKA retinoids acid syndrome - can include: Fever Peripheral edema Pulmonary infiltrates Respiratory distress Hypotension Renal and hepatic dysfunction Rash Pleural and pericardial effusions
Differentiation Syndrome cause
~ 25% patients with acute promyelocytic leukemia during induction therapy with all-trans retinoids acid (tretinoin) or arsenic trioxide
Complications of tunneled pleural catheters
Infection < 5% (often responds to antibiotic treatment without catheter removal)
Plural loculations (can be improved with intrapleural fibrinolytic therapy)
Catheter displacement 1-3%
Tumor tracking .5-3% (usually mesothelioma)
Rituximab description
Chimeric immunoglobulin G1 directed against CD20, targeting B cell lineages (pre-B cell through pre-plasma cell)
Rituximab MOA
Induces antibody dependent, cell mediated lysis
Rituximab complications
Hypogammaglobulinemia in certain population
Possible altered T-cell immunity (not lymphopenia)
